Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy

Radiother Oncol. 2018 Jul;128(1):154-160. doi: 10.1016/j.radonc.2017.11.028. Epub 2017 Dec 14.

Abstract

Background and purpose: Circulating lymphocytes are exquisitely sensitive to radiation exposure, even to low scattered doses which can vary drastically between radiation modalities. We compared the relative risk of radiation-induced lymphopenia between intensity modulated radiation therapy (IMRT) or proton beam therapy (PBT) in esophageal cancer (EC) patients undergoing neoadjuvant chemoradiation therapy (nCRT).

Material and methods: EC patients treated with IMRT and PBT were propensity matched based on key clinical variables. Treatment-associated lymphopenia was graded using CTCAE v.4.0. Using matched cohorts, univariate and multivariable multiple logistic regression was used to identify factors associated with increased risk of grade 4 lymphopenia as well as characterize their relative contributions.

Results: Among the 480 patients treated with nCRT, 136 IMRT patients were propensity score matched with 136 PBT patients. In the matched groups, a greater proportion of the IMRT patients (55/136, 40.4%) developed grade 4 lymphopenia during nCRT compared with the PBT patients (24/136, 17.6%, P < 0.0001). On multivariable analysis, PBT was significantly associated with a reduction in grade 4 lymphopenia risk (odds ratio, 0.29; 95% confidence interval, 0.16-0.52; P < 0.0001).

Conclusion: PBT is associated with significant risk reduction in grade 4 lymphopenia during nCRT in esophageal cancer.

Keywords: Chemoradiation; Esophageal cancer; Intensity modulated radiation therapy; Lymphopenia; Proton beam therapy.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Chemoradiotherapy / adverse effects*
  • Esophageal Neoplasms / therapy*
  • Female
  • Humans
  • Lymphopenia / etiology*
  • Male
  • Middle Aged
  • Neoadjuvant Therapy / adverse effects
  • Photons / adverse effects*
  • Propensity Score
  • Proton Therapy / adverse effects*
  • Radiation Injuries / etiology*
  • Radiotherapy, Intensity-Modulated / adverse effects*